Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Jonathan Schwartz
Accepted Abstracts: J Clin Exp Dermatol Res
T his presentation is an overview of how stem cell therapies are being performed globally. The presentation entails an overview of the different methods of harvesting and obtaining stem cells through various methodologies and the various ways the patients are receiving the stem cells. The presentation will also go into detail on the various applications for stem cell therapies and also the clinical studies currently underway for treatments of various conditions, including illness, disease, physical conditions and cosmetic and aesthetic applications. The discussion will also entail a detailed report on some of the drawbacks and false claims made by unethical practitioners who are making claims that cannot be validated or verified through independent third party analysis, lab results and clinical studies. The presentation will also go into detail on all of the newest devices and services that have recently become commercially available for regenerative medicine and where these technologies are being utilized. The science of regenerative medicine and stem cell technologies continue to advance but the commercialization aspects of utilizing these therapies are problematic as each of these need to be cleared through Healthcare Ministries and be in compliance with regulations as established by each country individually. Navigating through the registration process is a matter of great difficulty because the science is ahead of the regulations. The discussion will entail how to get products registered and the hurdles that need to be overcome to establish a presence internationally.
Jonathan Schwartz has over 30 years doing International business consulting for emerging medical technologies and has been focused on stem cell technologies and regenerative medicine for the past six years. He currently is the Managing Director of the Regenerative Cellular Institute in the United States and does business consulting for several companies globally, including, Mystem, Bioquark, WinCell, StemCells21, IntellihealthPlus, Al Mediq, Glo PRP, WeHealPlus, and Arpwave. He has previously worked in many capacities with Spacelabs Medical, GE Healthcare, Intellicell Biosciences, Coloplast, and Smith and Nephew. He has degrees from Queens College, Almeda University and NYU Medical School.